Novo Nordisk has announced breakthrough results from its PIONEER TEENS trial, proving that oral semaglutide for type 2 diabetes in children offers superior glycemic control and a well-tolerated safety profile for adolescents.
Novo Nordisk and United Biotechnology announce that their jointly developed UBT251 triple agonist targeting GLP-1, GIP, and glucagon receptors outperformed semaglutide 1 mg in a 24-week Chinese phase 2 trial, setting the stage for global phase 3 development.
Groundbreaking clinical trial demonstrates that FreeStyle Libre continuous glucose monitoring technology significantly improves glucose management in people with Type 2 diabetes using basal insulin therapy, with patients achieving better HbA1c reduction and more time spent in healthy glucose ranges compared to traditional fingerstick monitoring.
Eli Lilly has announced positive late-stage trial results for orforglipron, its investigational once-daily oral GLP-1 drug. In Phase 3 studies, orforglipron demonstrated superior blood sugar control and significant weight loss in adults with type 2 diabetes, outperforming other existing medications. These results position it as a potential new standard of care and a convenient oral alternative to injectable treatments.
Eli Lilly and Company announced positive topline results from its SURPASS-PEDS Phase 3 trial for Mounjaro (tirzepatide). The study, which evaluated the GIP/GLP-1 dual receptor agonist in children and adolescents with type 2 diabetes, demonstrated substantial and statistically significant improvements in blood sugar control and weight management, with a safety profile consistent with adult studies.
Semaglutide has transformed obesity and diabetes care, offering significant weight loss and glucose control with once-weekly dosing. Here’s a look at its clinical promise and expanding role in medicine.
